Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Operating Leases (2018 - 2025)

Cytokinetics (CYTK) has disclosed Operating Leases for 8 consecutive years, with $108.0 million as the latest value for Q4 2025.

  • Quarterly Operating Leases changed N/A to $108.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $108.0 million through Dec 2025, changed N/A year-over-year, with the annual reading at $108.0 million for FY2025, N/A changed from the prior year.
  • Operating Leases for Q4 2025 was $108.0 million at Cytokinetics, down from $110.7 million in the prior quarter.
  • The five-year high for Operating Leases was $126.9 million in Q4 2022, with the low at $85.3 million in Q1 2021.
  • Average Operating Leases over 5 years is $114.6 million, with a median of $114.4 million recorded in 2022.
  • The sharpest move saw Operating Leases surged 25406.59% in 2021, then dropped 6.11% in 2024.
  • Over 5 years, Operating Leases stood at $112.2 million in 2021, then increased by 13.07% to $126.9 million in 2022, then fell by 5.1% to $120.4 million in 2023, then decreased by 4.71% to $114.8 million in 2024, then dropped by 5.91% to $108.0 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $108.0 million, $110.7 million, and $111.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.